臨床検査54巻11号

2010年10月発行

特集 新時代のワクチン戦略について考える 各論 3. 期待されているこれからのワクチン

5) RSV―世界の開発状況

著者： 堤裕幸¹ 要藤裕孝¹

所属機関： ¹札幌医科大学医学部小児科

ページ範囲：P.1422 - P.1428

RSウイルス(RSV)感染症により入院加療を要する例の60％以上が1歳未満であり，重症RSV感染症のピークは生後2～7か月なので，RSVワクチンは生後数週間以内に投与される必要がある．生後早期のワクチンが有効であるためには乳児の免疫学的未熟性や，母体移行抗体の免疫抑制を克服する必要がある．ワクチン開発は1960年代の米国でのホルマリン不活化ワクチン以降，温度感受性変異株，精製F蛋白ワクチンなどの開発が進められているが，いまだ実用に足るものはない．

参考文献

1) Kuroiwa Y, Nagai K, Okita L, et al:A phylogenetic study of human respiratory syncytial viruses group A and B strains isolated in two cities in Japan from 1980-2002. J Med Virol　76：241-247，2005

2) 浅沼秀臣，新飯田裕一，堤裕幸：アンケート調査によるRSウイルス感染症入院例の検討．日小児会誌　108：395-400，2004

3) Crowe JE Jr, Williams JV:Immunology of viral respiratory tract infection in infancy. Pediatr Respir Rev　4：112-119，2003

4) Piedra PA:Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J　22：S94-S99，2003

5) Kapikian AZ, Mitchell RH, Chanock RM, et al:An epidemiologic study of altered clinical reactivity to respiratory syncitial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol　89：405-421，1969

6) Murphy BR, Walsh EE:Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol　26：1595-1597，1988

7) Delgado MF, Coviello S, Monsalvo AC, et al:Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med　15：34-41，2009

8) Connors M, Giese NA, Kulkarni AB, et al:Enhanced pulmonary histopathology induced by respiratory syncytila virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol　68：5321-5325，1994

9) Karron RA, Wright PF, Belshe RB, et al:Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis　191：1093-1104，2005

10) Wright PF, Karron RA, Belshe RB, et al:Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis　182：1331-1342，2000

11) Collins PL, Murphy BR:New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc　2：166-173，2005

12) Teng MN, Whitehead SS, Bermingham A, et al:Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol　74：9317-9321，2000

13) Whitehead SS, Bukreyev A, Teng MN, et al:Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol　73：3438-3442，1999

14) Schmidt AC, Wenzke DR, McAuliffe JM, et al:Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol　76：1089-1099，2002

15) Connors M, Collins PL, Firestone CY, et al:Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Vaccine　10：475-484，1992

16) Waris ME, Tsou C, Erdman DD, et al:Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol　71：6935-6939，1997

17) Piedra PA, Cron SG, Jewell A, et al:Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus:a multicenter trial in children with cystic fibrosis. Vaccine　21：2448-2460，2003

18) Munoz FM, Piedra PA, Glezen WP:Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine　21：3465-3467，2003

19) Power UF, Nguyen TN, Rietveld E, et al:Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis　184：1456-1460，2001

20) Tripp RA, Jones LP, Haynes LM, et al:CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol　2：732-738，2001

21) Harcourt J, Alvarez R, Jones LP, et al:Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1＋ T cell responses. J Immunol　176：1600-1608，2006

22) Zhang W, Choi Y, Haynes LM, et al:Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol　84：1148-1157，2010

23) Malley R, DeVincenzo J, Ramilo O, et al:Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis　178：1555-1561，1998

24) Wu H, Pfarr DS, Johnson S, et al:Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol　368：652-665，2007